Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022
Talis Biomedical Corporation (TLIS) has announced that it will report its first quarter financial results on May 10, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talis Biomedical Corporation (TLIS) has announced that it will report its first quarter financial results on May 10, 2022, after market close. The company will host a conference call at 1:30 PM PT (4:30 PM ET) to discuss these results. Interested parties can join via telephone or watch the webcast on their investor website. Talis is focused on improving health equity through accurate infectious disease testing, particularly with its Talis One system, which has received Emergency Use Authorization from the FDA for COVID-19 testing.
Positive
- Upcoming financial report scheduled for May 10, 2022.
- Talis One system received Emergency Use Authorization from the FDA.
Negative
- None.
Details
News Market Reaction – TLIS
The recorded move for TLIS in the trading session of this news was -3.54%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 8872347. A live and archived webcast of the event can be accessed via the News & Events page of the investor section of Talis Biomedical’s website at www.talis.bio.
About Talis Biomedical
Talis is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis OneTM system to enable accurate, low cost, and rapid molecular testing. The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for use of the Talis One COVID-19 Test System in a variety of healthcare settings. For more information, visit talisbio.com.
Contact
Media & Investors
Emily Faucette
ir@talisbio.com
415-595-9407
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.